OpenAlex
PricingAboutJobs
Log inGet started
Work

Potent and Selective Inhibition of Polycythemia by the Quinoxaline JAK2 Inhibitor NVP-BSK805

HTML

Year: 2010
Type: article
Source: Molecular Cancer Therapeutics
DOI: 10.1158/1535-7163.mct-10-0053
Authors: Fabienne Baffert, Catherine H. Régnier, Alain De Pover, Carole Pissot-Soldermann, Gisele A. Tavares, Francesca Blasco, Josef Brueggen, Patrick Chène, Peter Drueckes, Dirk Erdmann, Pascal Furet, Marc Gerspacher, Marc Lang, David Ledieu, Lynda Nolan, Stephan Ruetz, Joerg Trappe, Eric Vangrevelinghe, Markus Wartmann, Lorenza Wyder, Francesco Hofmann, Thomas Radimerski
Institutions: Novartis (Switzerland), Novartis Institutes for BioMedical Research
Language: English

Topic: Myeloproliferative Neoplasms: Diagnosis and Treatment
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Keywords: JAK2 inhibitors, JAK2 V617F mutation, polycythemia, quinoxaline, myeloproliferative neoplasms, polycythemia vera, essential thrombocythemia, primary myelofibrosis, STAT5 phosphorylation, kinase selectivity, ATP-competitive inhibition, extramedullary erythropoiesis, oral bioavailability
SDG: Good health and well-being

Open Access status: closed
OpenAlex ID: W2130062751
FWCI: 6.139
Cites: 41
Cited by: 135
Related to: 9
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Subscribe
Supporters
Legal
Privacy
Accessibility
Terms
Security